Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas.
Division of Biology, Chemistry and Materials Science, CDRH/OSEL, US Food and Drug Administration, Silver Spring, Maryland.
Environ Mol Mutagen. 2020 Jan;61(1):152-175. doi: 10.1002/em.22326. Epub 2019 Oct 6.
Cancer driver mutations (CDMs) are necessary and causal for carcinogenesis and have advantages as reporters of carcinogenic risk. However, little progress has been made toward developing measurements of CDMs as biomarkers for use in cancer risk assessment. Impediments for using a CDM-based metric to inform cancer risk include the complexity and stochastic nature of carcinogenesis, technical difficulty in quantifying low-frequency CDMs, and lack of established relationships between cancer driver mutant fractions and tumor incidence. Through literature review and database analyses, this review identifies the most promising targets to investigate as biomarkers of cancer risk. Mutational hotspots were discerned within the 20 most mutated genes across the 10 deadliest cancers. Forty genes were identified that encompass 108 mutational hotspot codons overrepresented in the COSMIC database; 424 different mutations within these hotspot codons account for approximately 63,000 tumors and their prevalence across tumor types is described. The review summarizes literature on the prevalence of CDMs in normal tissues and suggests such mutations are direct and indirect substrates for chemical carcinogenesis, which occurs in a spatially stochastic manner. Evidence that hotspot CDMs (hCDMs) frequently occur as tumor subpopulations is presented, indicating COSMIC data may underestimate mutation prevalence. Analyses of online databases show that genes containing hCDMs are enriched in functions related to intercellular communication. In its totality, the review provides a roadmap for the development of tissue-specific, CDM-based biomarkers of carcinogenic potential, comprised of batteries of hCDMs and can be measured by error-correct next-generation sequencing. Environ. Mol. Mutagen. 61:152-175, 2020. Published 2019. This article is a U.S. Government work and is in the public domain in the USA. Environmental and Molecular Mutagenesis published by Wiley Periodicals, Inc. on behalf of Environmental Mutagen Society.
癌症驱动突变(Cancer driver mutations,CDMs)是致癌作用所必需的和因果性的,并且作为致癌风险的报告具有优势。然而,在将 CDM 开发为癌症风险评估用生物标志物方面,几乎没有取得任何进展。使用基于 CDM 的指标来告知癌症风险存在的障碍包括致癌作用的复杂性和随机性、量化低频 CDM 的技术难度以及癌症驱动突变分数与肿瘤发病率之间缺乏既定关系。通过文献回顾和数据库分析,本综述确定了最有希望作为癌症风险生物标志物进行研究的靶标。在十种最致命癌症的 20 个最常突变基因中,发现了突变热点。确定了 40 个基因,这些基因包含 COSMIC 数据库中过度表达的 108 个突变热点密码子;这些热点密码子内的 424 个不同突变大约占 63000 个肿瘤,并且描述了它们在肿瘤类型中的普遍性。综述总结了关于正常组织中 CDM 普遍性的文献,并表明这些突变是化学致癌作用的直接和间接底物,而化学致癌作用以空间随机的方式发生。提供了热点 CDM(hCDM)经常作为肿瘤亚群出现的证据,表明 COSMIC 数据可能低估了突变的普遍性。对在线数据库的分析表明,含有 hCDM 的基因在与细胞间通讯相关的功能中富集。总的来说,本综述为开发基于组织的、CDM 的致癌潜能生物标志物提供了路线图,这些生物标志物由 hCDM 组成,并且可以通过纠错下一代测序进行测量。环境与分子突变,61:152-175,2020. 2019 年出版。本文是美国政府的工作,在美国属于公有领域。 Wiley Periodicals, Inc. 代表环境诱变学会出版环境与分子突变。